Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2

被引:40
作者
Vokurka, S. [1 ]
Steinerova, K. [1 ]
Karas, M. [1 ]
Koza, V. [1 ]
机构
[1] Univ Hosp Plzen Pilsen, Dept Haematooncol, Plzen 30460, Pilsen, Czech Republic
关键词
oral mucositis; melphalan; stem cell transplantation; toxicity; graft-versus-host disease; VERSUS-HOST-DISEASE; HIGH-DOSE MELPHALAN; MARROW-TRANSPLANTATION; CHEMOTHERAPY; FLUDARABINE; PREVENTION; RECIPIENTS; THERAPY; MYELOMA;
D O I
10.1038/bmt.2009.66
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The fludarabine ( FLU)/melphalan (MEL) conditioning regimen containing FLU and high-dose MEL was analyzed in comparison with the BU/CY2 regimen to characterize oral mucositis ( OM) and risk factors. OM incidence significantly varied between BU/CY2 and FLU/ MEL ( 100 vs 78%, P = 0.004), but the incidence of severe OM grades 3-4 WHO and kinetics of OM were fully comparable. Patients with OM persisting on day +21 had more acute GVHD (68 vs 32%, P = 0.005), which tended to occur earlier than among those without such prolonged OM. Multivariate analysis showed significant dependency of acute GVHD on severity and prolonged duration of OM and significant correlation between OM severity and its prolonged duration. Body surface area-based dosing in the FLU/ MEL regimen led to a wide range of MEL doses administered per kilogram body weight (2.5-5.2 mg/kg, median 3.5). In multivariate analysis, MEL dose per kilogram of body weight was found to be a significant predictor of OM incidence and severity. Female gender and lower body mass index were less important variables than the fact that the actual dose of MEL administered per kilogram of body weight was relatively high when the dosage was calculated on the basis of body surface area. Bone Marrow Transplantation ( 2009) 44, 601-605; doi: 10.1038/bmt.2009.66; published online 6 April 2009
引用
收藏
页码:601 / 605
页数:5
相关论文
共 50 条
  • [41] Clinical Characteristics and Prognostic Factors of Nephrotic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation
    Tu, Yan
    Yan, Mengni
    Zhang, Mingming
    Luo, Yi
    Shi, Jimin
    Zhao, Yanmin
    Wang, Rending
    Wang, Huiping
    Fu, Huarui
    Tan, Yamin
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2024, 85 (10)
  • [42] Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
    Schmid, Christoph
    Labopin, Myriam
    Nagler, Arnon
    Niederwieser, Dietger
    Castagna, Luca
    Tabrizi, Reza
    Stadler, Michael
    Kuball, Juergen
    Cornelissen, Jan
    Vorlicek, Jiri
    Socie, Gerard
    Falda, Michele
    Vindelov, Lars
    Ljungman, Per
    Jackson, Graham
    Kroeger, Nicolaus
    Rank, Andreas
    Polge, Emmanuelle
    Rocha, Vanderson
    Mohty, Mohamad
    BLOOD, 2012, 119 (06) : 1599 - 1606
  • [43] Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning
    Barba, P.
    Martino, R.
    Perez-Simon, J. A.
    Fernandez-Aviles, F.
    Pinana, J. L.
    Valcarcel, D.
    Campos-Varela, I.
    Lopez-Anglada, L.
    Rovira, M.
    Novelli, S.
    Lopez-Corral, L.
    Carreras, E.
    Sierra, J.
    BONE MARROW TRANSPLANTATION, 2012, 47 (10) : 1343 - 1349
  • [44] Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation
    Huetter-Kroenke, Marie Luise
    Neagoie, Adela
    Blau, Igor Wolfgang
    Wais, Verena
    Vuong, Lam
    Gantner, Andrea
    Ahn, Johann
    Penack, Olaf
    Schnell, Jacqueline
    Nogai, Klaus Axel
    Eberspaecher, Bettina
    Saadati, Maral
    Benner, Axel
    Bullinger, Lars
    Doehner, Hartmut
    Bunjes, Donald
    Sala, Elisa
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [45] New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2
    Y S Chae
    S K Sohn
    J G Kim
    Y Y Cho
    J H Moon
    H J Shin
    J S Chung
    G J Cho
    D H Yang
    J-J Lee
    Y-K Kim
    H-J Kim
    Bone Marrow Transplantation, 2007, 40 : 541 - 547
  • [46] New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2
    Chae, Y. S.
    Sohn, S. K.
    Kim, J. G.
    Cho, Y. Y.
    Moon, J. H.
    Shin, H. J.
    Chung, J. S.
    Cho, G. J.
    Yang, D. H.
    Lee, J-J
    Kim, Y-K
    Kim, H-J
    BONE MARROW TRANSPLANTATION, 2007, 40 (06) : 541 - 547
  • [47] Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplantation: a case report
    Annaloro, Claudio
    Costa, Antonella
    Fracchiolla, Nicola S.
    Mometto, Gabriella
    Artuso, Silvia
    Saporiti, Giorgia
    Tagliaferri, Elena
    Grifoni, Federica
    Onida, Francesco
    Cortelezzi, Agostino
    CLINICAL CASE REPORTS, 2015, 3 (07): : 650 - 655
  • [48] Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation
    Ueda, Tomoaki
    Maeda, Tetsuo
    Kusakabe, Shinsuke
    Fujita, Jiro
    Fukushima, Kentaro
    Yokota, Takafumi
    Shibayama, Hirohiko
    Tomiyama, Yoshiaki
    Kanakura, Yuzuru
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (02) : 197 - 205
  • [49] Risk factors of human herpesvirus 6 encephalitis/myelitis after allogeneic hematopoietic stem cell transplantation
    Miyashita, Naohiro
    Endo, Tomoyuki
    Onozawa, Masahiro
    Hashimoto, Daigo
    Kondo, Takeshi
    Fujimoto, Katsuya
    Kahata, Kaoru
    Sugita, Junichi
    Goto, Hideki
    Matsukawa, Toshihiro
    Hashino, Satoshi
    Teshima, Takanori
    TRANSPLANT INFECTIOUS DISEASE, 2017, 19 (03)
  • [50] Incidence and Risk Factors for Acute Kidney Injury after Allogeneic Stem Cell Transplantation: A Prospective Study
    Andronesi, Andreea
    Sorohan, Bogdan
    Burcea, Andreea
    Lipan, Lavinia
    Stanescu, Cristina
    Craciun, Oana
    Stefan, Laura
    Ranete, Adela
    Varady, Zsofia
    Ungureanu, Oana
    Lupusoru, Gabriela
    Agrigoroaei, Gabriela
    Andronesi, Danut
    Iliuta, Luminita
    Obrisca, Bogdan
    Tanase, Alina
    BIOMEDICINES, 2022, 10 (02)